Baxter ($BAX) widened its hemophilia franchise on the eve of its breakup, winning FDA approval for a drug that treats a rare form of the bleeding disorder. Obizur is a treatment for acquired hemophilia A that works by replacing Factor VIII, the missing or deficient protein that keeps patients' blood from properly clotting. Unlike inherited forms of the disease, acquired hemophilia A develops later in life from a variety of causes and affects only about one in a million people, according to Baxter. The latest approval comes as the company plans to split in two next year, keeping its med tech business under the old name and hiving off its biopharma operation into a new firm called Baxalta. FDA release | Baxter release